cmp

CMP-5 2HCl is a anthelmintic agent. CMP-5 2HCl shows EC100 of 5μM against H. contortus in vitro.

Smurf-1 modulator CMP Example 20 (Smurf-1-IN-20) is a potent Smurf-1 modulator.

CMP-5 is a PRMT5 inhibitor with antiviral activity, inhibits PRMT5 methyltransferase activity, and can be used in the study of SARS virus infection.

CMP-Sialic acid (CMP-Neu5Ac) acts as an allosteric inhibitor of UDP-GlcNAc 2-epimerase, is a substrate for Golgi sialyltransferases, and is essential for the biosynthesis of sialic acid and its conjugates [1].

CMP-Sialic acid sodium salt (CMP-Neu5Ac sodium salt) is a variant inhibitor of UDP-GlcNAc 2-epimerase, the activated form of sialic acid, which is widely found in animals and is involved in the metabolism of organisms.

CMP-5 hydrochloride is a potent and selective PRMT5 inhibitor, while displays no activity against PRMT1 4 7 enzymes. It selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations.

Cytidine 5'-monophosphate (5'-Cytidylic acid) is a nucleotide integral to RNA, comprising the nucleobase cytosine, pentose ribose, and phosphate groups.

CMP8 is a selective ligand for estrogen receptor. CMP8 binds to the mutant estrogen receptor ligand binding domain (ERLBD). CMP8 has IC50 values of 29 nM , 41 nM, 1100 nM and 2200 nM for MGERα, MGRERα, hERα and hERβ, respectively.

Indantadol HCl (CHF-3381) is a NMDA antagonist and nonselective MAO inhibitor.

CMP98, a proteolysis targeting chimera (PROTAC), exhibits a lack of VHL degradation efficacy. It can function as a negative control compound in comparison to CM11. CMP98 comprises two von Hippel-Lindau ligands operating within their active domains.

CMP3a is a NEK2 kinase inhibitor. CMP3a efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase E

Pyridone 6 (JAK Inhibitor)(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); displaying significantly weaker affinities (130 nM to 10 mM) for other protein tyrosine kinases.

Cytarabine 5′-monophosphate (ara-CMP), an active metabolite of the nucleoside analog cytarabine formed by deoxycytidine kinase, is incorporated into DNA by DNA polymerase α, significantly slowing DNA synthesis. It inhibits nuclear and mitochondrial DNA replication in S. cerevisiae at 15 mM and improves survival in an L1210 murine leukemia model at 3.5-75.1 mg/kg.

Cytidine 3'-monophosphate, a ribonucleotide, results from the hydrolysis of cytidine 2’,3’-cyclic monophosphate via RNase—a process that cytidine 3'-monophosphate itself inhibits. Additionally, it can be dephosphorylated to cytidine by 3’-nucleotidase.

Ancitabine hydrochloride (NSC 145668 HCl) is the hydrochloride salt of a cytarabine congener prodrug with antineoplastic activity. Upon administration, ancitabine is slowly hydrolyzed into cytarabine. Subsequently, cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. Cytarabine agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Compared to cytarabine, a more prolonged, consistent cytarabine-mediated therapeutic effect may be achieved with ancitabine because of the slow hydrolytic conversion of ancitabine to cytarabine.

Cytidine 5'-diphosphate trisodium salt (CDP) catalyzes the production of Cytidine triphosphate (CTP) for DNA and RNA synthesis by transferring a phosphoryl group from ATP to cytidine monophosphate (CMP) through the action of uridine monophosphate kinase (UMPK).

(2-Aminoethyl)phosphonic acid (2-Aminoethylphosphonic acid) is primarily detected in urine. (2-Aminoethyl)phosphonic acid participates in many enzymatic reactions and is also the parent compound of other transformation products, including but not limited to ceramide 2-(methylamino)ethylphosphonate, N-(2-phosphineethyl)cholamide and CMP-2-aminoethylphosphonate.

CMPD1 is a non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor(apparent Ki (Kiapp): 330 nM).

Sulbactum Sodium (5'-CDP) is synthesized from cytidine monophosphate (CMP) or uridine monophosphate (UMP) by the transfer of phosphoryl group, catalyzed by the enzyme uridylate kinase (UMPK)

CMPF is a microtubule protein inhibitor that can be used to study tumors.

m7GpppCmpG, a trinucleotide cap analogue and oligonucleotide, serves as a chemical tool for the production of RNA with either cap 0 or cap 1 structures, facilitating research and manufacturing processes involving these RNA caps [1].

CMPD101 is a membrane-permeable small-molecule inhibitor of GRK2 3 (IC50: 18 nM and 5.4 nM). Which can be used for the study of heart failure. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC50s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively.

Cmpd-A is a time-dependent CENP-E inhibitor with potent antitumor activity. Cmpd-A inhibits the ATPase activity of the CENP-E motor domain, acting as a time-dependent inhibitor with an ATP-competitive-like behavior. Cmpd-A causes chromosome misalignment on the metaphase plate, leading to prolonged mitotic arrest. Treatment with Cmpd-A induces antiproliferation in multiple cancer cell lines.

Cmpd 339509 is a DprE1 inhibitor. DprE1 is an epimerase required for cell wall biosynthesis.

CMPI hydrochloride, a potent and selective nAChR agonist, functions as a positive allosteric modulator (PAM) specifically targeting the α4:α4 subunit interface of the nAChR. It enhances the response of the (α4)3(β2)2 nAChR to acetylcholine (ACh) (10 μM) with an EC 50 of 0.26 μM. With its potential for researching nicotine dependence and various neuropsychiatric conditions linked to reduced brain cholinergic activity, CMPI hydrochloride stands as a significant compound in neurological research.

Potent positive allosteric modulator of α4β2 nAChRs (EC50 values are 20 and 18 nM for rat and human, respectively). Selective for hα4β2 over hα3β2, hα3β4 and hα7. Inhibits (α4)2(β2)3, muscle-type and Torpedo nAChRs (IC50 values are 0.5, 0.7 and 0.2 μM, respectively), but not (α4)3(β2)2 receptors. Exhibits ability to photoincorporate into aliphatic and nucleophilic amino acid side chains. Hamouda (2016) Photolabeling a nicotinic acetylcholine receptor (nAChR) with an (α4)3(β2)2 nAChR-selective positive allosteric modulator. Mol.Pharmacol. 89 575 PMID:26976945 |Albrecht et al (2008) Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant α4β2 nicotinic acetylcholine receptor potentiators. Bioorg.Med.Chem.Lett. 18 5209 PMID:18789861 |Wang et al (2017) Unraveling amino acid residues critical for allosteric potentiation of (α4)3(β2)2-type nicotinic acetylcholine receptor responses. J.Biol.Chem. 292 9988 PMID:28446611

CMPDA is a positive allosteric modulator of AMPA receptors [EC50s: 45.4 nM 63.4 nM for GluA2i GluA2o receptor].

CMPD167 (MRK-1) is a potent, orally active inhibitor of CCR5 with significant in vitro antiviral efficacy [1].

2'-Deoxycytidine-5'-monophosphoric acid (2'-Deoxycytidine 5'-monophosphate) is a substrate of uridine monophosphate (UMP) cytidine monophosphate (CMP) kinase (EC 2.7.4.4) that forms dCDP, which, upon phosphorylation to dCTP, supports DNA biosynthesis.

Uridine-5’-monophosphate (UMP) is a ribonucleotide.1It is formedviadecarboxylation of orotidine-5’-monophosphate (5’-OMP) by OMP decarboxylase. UMP is further phosphorylated by UMP-CMP kinase to form UDP and UTP during nucleic acid biosynthesis. Formulations containing UMP have been used as dietary supplements. 1.Berg, J.M., Tymoczko, J.L., and Stryer, L.Nucleotide BiosynthesisBiochemistry(2002)

5-Azacytidine 5′-triphosphate (5-aza-CMP), a cytidine analog, selectively inhibits the incorporation of [^3H]CTP into RNA during the DNA-dependent RNA polymerase reaction without affecting the incorporation of [^3H]UTP [1].

Vidutolimod (CMP-001), a CpG-A oligodeoxynucleotide and Toll-like receptor 9 (TLR9) agonist, activates plasmacytoid dendritic cells (pDCs) and induces the release of interferon alpha (IFNα), initiating a series of anti-tumor immune responses.

Alpha-2-3,6-sialidase (BiNanH2), a sialyltransferase commonly utilized in biochemical research, catalyzes the transfer of α-2,3/2,6-sialyl from CMP-Neu5Ac to galactoside acceptors [1].